Research Overview
· Last Reviewed May 3, 2026· PSI Editorial Board· IndependentCan Peptides Help With Insulin Resistance?
The honest map across 8 insulin resistance scenarios — what is FDA-approved for weight management, where lifestyle and metformin rule, and how peptide therapy fits.
WHICH IR CONTEXT?
Insulin Resistance Context
Animal Studies
Human Trials
Prediabetes lifestyle-first prevention
validated DPP framework
Prediabetes with high BMI considering pharmacotherapy
metformin per ADA select populations
Obesity with insulin resistance and prediabetes
FDA-approved Saxenda chronic weight management
Obesity with insulin resistance wanting maximum weight loss
FDA-approved Zepbound chronic weight management
Obesity with insulin resistance and CV risk
FDA-approved Wegovy chronic weight management
PCOS with insulin resistance contributor
lifestyle + metformin + GLP-1 RA off-label considerations
MASLD with insulin resistance contributor
lifestyle + weight management foundations
Phase 3 triple-agonist research access
investigational class context
How counts are scaled → · Tap any row to see the studies →
Quick Answer
Insulin resistance and prediabetes have well-characterized validated approaches in clinical practice. Foundations include comprehensive evaluation by primary care, endocrinology, or weight medicine specialty. Workup covers HbA1c, fasting glucose, oral glucose tolerance test, and metabolic panel per ADA Standards of Care. Additional assessment includes BMI, waist circumference, lipid panel, blood pressure, and cardiovascular risk evaluation.
Lifestyle intervention is validated first-line per ADA Standards of Care. The Diabetes Prevention Program demonstrated 58 percent reduction in T2D progression through structured lifestyle intervention. Components include dietary pattern, physical activity 150 minutes weekly, and weight loss target of 5 to 7 percent.
Liraglutide is FDA-approved as Saxenda for chronic weight management. The SCALE Obesity and Prediabetes Phase 3 trial directly studied prediabetes populations with weight reduction approximately 8 percent at 56 weeks.
Semaglutide is FDA-approved as Wegovy for chronic weight management. STEP-1 trial demonstrated weight reduction approximately 15 percent at 68 weeks with insulin sensitivity benefits.
Tirzepatide is FDA-approved as Zepbound for chronic weight management. SURMOUNT-1 trial demonstrated weight reduction approximately 21 percent at 72 weeks with insulin sensitivity benefits.
Retatrutide is investigational with Phase 3 TRIUMPH-1 program at Eli Lilly. The compound is a triple GLP-1/GIP/glucagon receptor agonist with Phase 2 weight reduction approximately 24 percent at 48 weeks.
The honest framing: lifestyle intervention is validated first-line for insulin resistance and prediabetes. Metformin is FDA-approved for select populations. GLP-1 RA weight management addresses underlying obesity contributor. For broader context, see Peptides for Metabolic Health, Peptides for Type 2 Diabetes, and Peptides for Weight Loss.
Lifestyle intervention vs metformin first-line for prediabetes
Diabetes Prevention Program-derived versus pharmacotherapy
Lifestyle intervention is validated first-line for prediabetes per ADA Standards of Care. The Diabetes Prevention Program (DPP) demonstrated 58 percent reduction in T2D progression through structured lifestyle intervention over the trial period. Components include dietary pattern modification, physical activity 150 minutes weekly, and weight loss target of 5 to 7 percent. The Diabetes Prevention Program Outcomes Study (DPPOS) confirmed sustained benefits over 15 years. CDC-recognized National Diabetes Prevention Program provides accessible structured framework.
Metformin is FDA-approved alternative for prediabetes prevention in select higher-risk populations per ADA Standards of Care. Indications include BMI 35 or higher, age under 60, history of gestational diabetes, or progressive hyperglycemia despite lifestyle intervention. The DPP demonstrated 31 percent reduction in T2D progression with metformin (less than the 58 percent with lifestyle intervention). The compound has decades of safety data, low cost with generic availability, and modest weight neutrality.
PSI's reading: lifestyle intervention through DPP-derived structured framework is validated first-line per current ADA Standards of Care for most prediabetes patients. Metformin is appropriate alternative for higher-risk populations meeting specific criteria. Combination of lifestyle and metformin is common in clinical practice. GLP-1 RA weight management addresses underlying obesity contributor when appropriate per FDA-approved Saxenda, Wegovy, and Zepbound indications.
Liraglutide SCALE Obesity and Prediabetes vs other GLP-1 RAs for IR
Direct prediabetes population evidence versus broader weight management
Liraglutide SCALE Obesity and Prediabetes Phase 3 trial directly studied prediabetes populations with weight reduction approximately 8 percent at 56 weeks. The trial demonstrated reduced progression to type 2 diabetes in prediabetes populations over 3 years. The compound holds FDA approval as Saxenda for chronic weight management with this direct prediabetes evidence base. Once-daily subcutaneous dosing offers alternative to weekly options.
Semaglutide STEP-1 trial and Tirzepatide SURMOUNT-1 trial studied broader overweight or obesity populations without diabetes. STEP-1 demonstrated approximately 15 percent weight reduction at 68 weeks. SURMOUNT-1 demonstrated approximately 21 percent weight reduction at 72 weeks. Both demonstrate insulin sensitivity benefits proportional to weight loss achieved. Direct prediabetes-specific Phase 3 evidence is more limited compared to Liraglutide SCALE.
PSI's reading: all three FDA-approved compounds (Liraglutide Saxenda, Semaglutide Wegovy, Tirzepatide Zepbound) are validated for chronic weight management in adults with obesity or overweight with comorbidity including prediabetes. Liraglutide has direct SCALE Obesity and Prediabetes trial evidence. Semaglutide and Tirzepatide demonstrate greater weight reduction with insulin sensitivity benefits proportional to weight loss. Patient selection considers individualized factors under specialty guidance.
GLP-1 RAs vs SGLT2 inhibitors for insulin resistance and prediabetes
Two emerging considerations beyond lifestyle and metformin
GLP-1 receptor agonists hold FDA-approved chronic weight management indications (Saxenda, Wegovy, Zepbound) with insulin sensitivity benefits through weight reduction. Liraglutide SCALE Obesity and Prediabetes directly studied this population. Mechanism is incretin signaling with central appetite reduction. Weight reduction translates to improvements in insulin sensitivity, fasting glucose, and HbA1c.
SGLT2 inhibitors are FDA-approved for type 2 diabetes (not prediabetes) with cardiovascular outcomes and chronic kidney disease indications. Mechanism is sodium-glucose cotransporter 2 inhibition with renal glucose excretion. Weight reduction is modest (approximately 2 to 3 kg). The class is not FDA-approved for prediabetes prevention or insulin resistance specifically. Off-label use for prediabetes prevention lacks Phase 3 outcome trial evidence in those contexts.
PSI's reading: GLP-1 RA weight management via FDA-approved Saxenda, Wegovy, and Zepbound addresses obesity-related insulin resistance with validated framework. SGLT2 inhibitors are not FDA-approved for prediabetes specifically. Lifestyle intervention remains validated first-line per ADA Standards of Care. Metformin is FDA-approved alternative for select populations. Specialty guidance ensures appropriate matching.
Comprehensive prediabetes prevention vs single-compound approach
Multi-factor intervention beyond pharmacotherapy
Insulin resistance and prediabetes have multiple contributors. Adiposity factors include obesity, visceral fat distribution, and metabolic syndrome. Lifestyle factors include dietary pattern, physical activity, sleep, and stress. Genetic factors and ethnicity affect risk. Comorbidities including PCOS, MASLD, and sleep apnea contribute. Comprehensive workup per ADA Standards of Care identifies contributing factors.
Validated approaches address each contributor. Lifestyle intervention through DPP-derived structured framework is validated first-line. Metformin addresses pharmacotherapy needs in select populations. GLP-1 RA weight management addresses obesity contributor with FDA-approved indications. Comorbidity management including PCOS, MASLD, and sleep apnea care is appropriate. Comprehensive specialty coordination integrates multi-factor approach.
PSI's reading: comprehensive prediabetes prevention by primary care, endocrinology, or weight medicine specialty identifies contributing factors and matches treatment. Lifestyle intervention through DPP-derived framework is validated first-line. Pharmacotherapy options including metformin and GLP-1 RA weight management address specific factors. Single-compound peptide approach without comprehensive evaluation bypasses essential lifestyle foundation. Off-label compounded peptide use is not validated practice.
The Compounds, Ranked by Evidence
Ordered by strength of controlled human data, not popularity.
Of the 4 peptides discussed for insulin resistance and prediabetes, three hold FDA approvals for chronic weight management with insulin sensitivity benefits through weight reduction. Semaglutide (Wegovy), Tirzepatide (Zepbound), and Liraglutide (Saxenda) are FDA-approved with substantial Phase 3 evidence. Liraglutide SCALE Obesity and Prediabetes trial directly studied this population. Retatrutide is in Phase 3 TRIUMPH-1 development at Eli Lilly. Validated standard-of-care including the Diabetes Prevention Program lifestyle framework (58 percent T2D reduction), metformin in select populations, GLP-1 RA weight management, and comprehensive metabolic monitoring under endocrinology, primary care, or weight medicine specialty guidance dominates evidence-graded insulin resistance and prediabetes prevention per ADA Standards of Care.
Liraglutide
FDA-approved Saxenda for chronic weight management. Direct SCALE Obesity and Prediabetes Phase 3 trial evidence in prediabetes populations.
Counts are PubMed-indexed papers and registered clinical trials. Scale: Strong 10+, Moderate 4–9, Limited 1–3, None 0. Methodology →
| Context | Animal Studies | Human Trials |
|---|---|---|
Chronic weight management with prediabetes FDA-approved Saxenda | 6 GLP-1 signaling effects on weight and glucose metabolism in animal models. | 8 SCALE Obesity and Prediabetes trial demonstrated weight reduction and reduced T2D progression in prediabetes populations. Pi-Sunyer 2015, le Roux 2017 |
Insulin sensitivity benefits via weight reduction | 4 Insulin sensitivity improvements in animal models. | 4 Improvements in insulin sensitivity proportional to weight loss achieved. |
Semaglutide
FDA-approved Wegovy for chronic weight management. STEP-1 weight reduction approximately 15 percent at 68 weeks plus SELECT cardiovascular outcomes.
| Context | Animal Studies | Human Trials |
|---|---|---|
Chronic weight management FDA-approved Wegovy | 6 Central appetite suppression effects in animal models. | 8 STEP-1 demonstrated approximately 15 percent weight reduction at 68 weeks. Wilding 2021 |
CV outcomes in overweight/obesity without diabetes | 4 Cardiovascular protective effects in animal models. | 6 SELECT demonstrated 20 percent reduction in MACE. Lincoff 2023 |
Tirzepatide
FDA-approved Zepbound for chronic weight management. SURMOUNT-1 weight reduction approximately 21 percent at 72 weeks; SURMOUNT-5 superior to Wegovy.
| Context | Animal Studies | Human Trials |
|---|---|---|
Chronic weight management FDA-approved Zepbound | 6 Dual incretin signaling effects on weight in animal models. | 8 SURMOUNT-1 demonstrated approximately 21 percent weight reduction at 72 weeks. Jastreboff 2022 |
Head-to-head efficacy SURMOUNT-5 vs Wegovy | 4 Comparative dual vs single-receptor effects. | 4 SURMOUNT-5 demonstrated superior weight reduction versus semaglutide. Aronne 2024 |
Retatrutide
Investigational; Phase 3 TRIUMPH-1 program at Eli Lilly. Triple GLP-1/GIP/glucagon agonist with Phase 2 weight reduction approximately 24 percent. Not FDA-approved.
| Context | Animal Studies | Human Trials |
|---|---|---|
Obesity weight management Phase 3 TRIUMPH-1 ongoing | 6 Triple incretin signaling evidence in obesity animal models. | 4 Phase 2 demonstrated approximately 24 percent weight reduction at 48 weeks. Jastreboff 2023 |
What's Marketed vs What's Studied
7 common claims, corrected.
“GLP-1 receptor agonists are first-line for prediabetes.”
Lifestyle intervention through DPP-derived structured framework is validated first-line for prediabetes per current ADA Standards of Care. Metformin is FDA-approved alternative for select higher-risk populations. GLP-1 RAs hold FDA approvals for chronic weight management (Saxenda, Wegovy, Zepbound) addressing the obesity contributor when appropriate per validated framework.
“I can self-treat prediabetes with peptides without lifestyle intervention.”
Lifestyle intervention through DPP-derived framework demonstrated 58 percent T2D reduction and is validated first-line. Pharmacotherapy including GLP-1 RA chronic weight management complements but does not replace lifestyle foundations. Comprehensive specialty guidance integrates lifestyle and pharmacotherapy.
“Compounded GLP-1 receptor agonists are equivalent to FDA-approved Saxenda, Wegovy, and Zepbound.”
FDA-approved Saxenda, Wegovy, and Zepbound have substantial Phase 3 evidence with quality control and regulatory oversight. Compounded peptides outside FDA-approved framework lack equivalent evidence and quality assurance. Clinical practice relies on FDA-approved products under specialty guidance.
“Insulin resistance is irreversible.”
Insulin resistance and prediabetes are reversible in many patients through sufficient weight loss, lifestyle intervention, or pharmacotherapy. The Diabetes Prevention Program demonstrated 58 percent reduction in progression to type 2 diabetes through structured lifestyle. Sustained intervention is required for sustained benefit. Most patients require ongoing monitoring.
“Metformin is too old to be effective for prediabetes prevention.”
Metformin remains FDA-approved alternative for prediabetes prevention in select higher-risk populations per current ADA Standards of Care. The Diabetes Prevention Program demonstrated 31 percent reduction in T2D progression with metformin. The compound has decades of safety data, low cost with generic availability, and modest weight neutrality. Indications include BMI 35 or higher, age under 60, or history of gestational diabetes.
“SGLT2 inhibitors prevent prediabetes progression.”
SGLT2 inhibitors are FDA-approved for type 2 diabetes, heart failure, and chronic kidney disease (not prediabetes specifically). Off-label use for prediabetes prevention lacks Phase 3 outcome trial evidence. Validated prediabetes prevention relies on lifestyle intervention, metformin in select populations, and GLP-1 RA chronic weight management for obesity-related insulin resistance.
“I can skip evaluation and start on weight management peptides immediately.”
Comprehensive evaluation by primary care, endocrinology, or weight medicine specialty identifies contributing factors and matches treatment per ADA Standards of Care. Workup includes HbA1c, fasting glucose, oral glucose tolerance test, lipid panel, BMI, and cardiovascular risk assessment. Self-treatment bypasses essential clinical assessment and validated framework.
If Considering Use, Here Is How to Be Safe
How to evaluate sources, verify quality, and find qualified physicians.
Get comprehensive evaluation.
HbA1c, fasting glucose, OGTT (any of these for diagnosis), lipid panel, metabolic panel, BMI, blood pressure, and cardiovascular risk assessment guide treatment decisions per ADA Standards of Care.
Establish primary care, endocrinology, or weight medicine.
Specialty evaluation determines appropriate therapy matching. CDC-recognized National Diabetes Prevention Program provides accessible structured lifestyle intervention with referral.
Match validated approaches to your situation.
Lifestyle intervention through DPP-derived framework is validated first-line. Metformin for select higher-risk populations. GLP-1 RA weight management for FDA-approved indications. Specialty guidance ensures matching.
Optimize lifestyle and validated foundations.
Mediterranean dietary pattern, physical activity 150 minutes weekly, weight loss target 5 to 7 percent, adequate sleep, stress management, smoking cessation, and limited alcohol form the validated foundation.
Approach compounded peptides cautiously.
FDA-approved Saxenda, Wegovy, and Zepbound have substantial Phase 3 evidence. Compounded peptides outside FDA-approved framework are not validated practice.
Address comorbidities when present.
PCOS, MASLD, sleep apnea, and metabolic syndrome contribute to insulin resistance. Comprehensive specialty coordination ensures multi-factor approach.
The regulatory landscape for insulin resistance and prediabetes peptides is evolving. No peptide is currently FDA-approved specifically for prediabetes prevention. Liraglutide (Saxenda), Semaglutide (Wegovy), and Tirzepatide (Zepbound) hold FDA approvals for chronic weight management which addresses the obesity contributor. Liraglutide SCALE Obesity and Prediabetes trial provides direct prediabetes population evidence. Retatrutide Phase 3 TRIUMPH-1 program at Eli Lilly is ongoing. Compounded GLP-1 receptor agonists have faced regulatory scrutiny during commercial supply normalization. PSI tracks these developments and updates this page as material changes occur.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Common Questions
Are any peptides FDA-approved for insulin resistance or prediabetes?
No peptide is FDA-approved specifically for insulin resistance or prediabetes prevention. Three peptides hold FDA approvals for chronic weight management (Saxenda, Wegovy, Zepbound) which addresses the obesity contributor with insulin sensitivity benefits through weight reduction. Liraglutide SCALE Obesity and Prediabetes trial directly studied prediabetes populations. Validated first-line for prediabetes per ADA Standards of Care is lifestyle intervention through DPP-derived structured framework. Metformin is FDA-approved alternative for select higher-risk populations.
What is the Diabetes Prevention Program?
The Diabetes Prevention Program (DPP) was a landmark NIH-funded clinical trial that established lifestyle intervention as validated first-line for prediabetes. Components included dietary pattern modification, physical activity 150 minutes per week, and weight loss target of 5 to 7 percent. Results demonstrated 58 percent reduction in progression to type 2 diabetes over the trial period. The Diabetes Prevention Program Outcomes Study (DPPOS) confirmed sustained benefits over 15 years. CDC-recognized National Diabetes Prevention Program provides accessible structured framework with in-person or online options nationwide.
Should I see an endocrinologist or primary care for prediabetes?
Primary care typically manages initial prediabetes evaluation, lifestyle intervention guidance, and routine management for many patients. Endocrinology specialty manages complex cases or those requiring pharmacotherapy escalation. Weight medicine specialty and obesity medicine manage chronic weight management with prediabetes. ADA Standards of Care provides framework. CDC-recognized National Diabetes Prevention Program offers accessible structured lifestyle intervention with referral from primary care.
What is the comprehensive evaluation for insulin resistance?
Comprehensive evaluation per ADA Standards of Care includes HbA1c, fasting plasma glucose, and 75-gram oral glucose tolerance test (any of these for prediabetes diagnosis). Additional testing includes lipid panel, metabolic panel, BMI, waist circumference, blood pressure, and cardiovascular risk assessment. Optional testing includes fasting insulin, HOMA-IR, and 2-hour insulin during OGTT. Comorbidity screening includes PCOS evaluation, MASLD assessment, and sleep apnea screening when appropriate.
When does prediabetes warrant pharmacotherapy?
Lifestyle intervention through DPP-derived structured framework is validated first-line per ADA Standards of Care for most prediabetes patients. Pharmacotherapy with metformin is FDA-approved alternative for select higher-risk populations including BMI 35 or higher, age under 60, history of gestational diabetes, or progressive hyperglycemia despite lifestyle intervention. GLP-1 RA chronic weight management is appropriate for adults meeting Saxenda, Wegovy, or Zepbound indications (BMI 30+ or BMI 27+ with comorbidity). Specialty guidance ensures appropriate matching.
What is the difference between insulin resistance and prediabetes?
Insulin resistance is a metabolic state where cells respond less to insulin signaling. Prediabetes is a clinical diagnosis defined by elevated glucose measures: HbA1c 5.7 to 6.4 percent, fasting glucose 100 to 125 mg/dL, or 2-hour OGTT 140 to 199 mg/dL per ADA Standards of Care. Insulin resistance often precedes and contributes to prediabetes. Both conditions benefit from lifestyle intervention, weight management, and metabolic optimization. Progression to type 2 diabetes is not inevitable with appropriate intervention.
How do GLP-1 receptor agonists help with insulin resistance?
GLP-1 receptor agonists improve insulin sensitivity primarily through weight reduction in insulin resistance and prediabetes contexts. Mechanism includes glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central appetite reduction. Weight reduction translates to corresponding improvements in insulin sensitivity, fasting glucose, and HbA1c. Liraglutide SCALE Obesity and Prediabetes trial demonstrated reduced T2D progression in prediabetes populations. Semaglutide STEP-1 and Tirzepatide SURMOUNT-1 trials demonstrated greater weight reduction with insulin sensitivity benefits.
What are the side effects of GLP-1 receptor agonists?
Common GLP-1 receptor agonist side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, and reduced appetite. GI symptoms are most common during dose titration. Less common effects include pancreatitis (boxed warning across class), gallbladder disease, and rare thyroid C-cell tumors in animal models. Contraindications include personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Pregnancy and certain GI conditions affect prescribing.
Can lifestyle intervention reverse prediabetes?
Yes. The Diabetes Prevention Program demonstrated 58 percent reduction in progression to type 2 diabetes through structured lifestyle intervention. Many patients achieve normalization of glucose measures with sustained intervention. Components include dietary pattern modification, physical activity 150 minutes weekly, and weight loss target of 5 to 7 percent. Mediterranean dietary pattern provides substantial validated cardiometabolic outcomes evidence. Sustained behavior change is required for sustained benefit. CDC-recognized National Diabetes Prevention Program provides accessible structured framework.
Is metformin still effective for prediabetes prevention?
Yes. Metformin remains FDA-approved alternative for prediabetes prevention in select higher-risk populations per current ADA Standards of Care. The Diabetes Prevention Program demonstrated 31 percent reduction in T2D progression with metformin. The compound has decades of safety data, low cost with generic availability, and modest weight neutrality. Indications include BMI 35 or higher, age under 60, history of gestational diabetes, or progressive hyperglycemia despite lifestyle intervention. Combination of lifestyle and metformin is common in clinical practice.
What about PCOS and insulin resistance?
Polycystic ovary syndrome (PCOS) is associated with insulin resistance in many affected women. Comprehensive PCOS management includes lifestyle intervention, weight management when appropriate, and pharmacotherapy options. Metformin is FDA-approved for type 2 diabetes and used off-label for PCOS-associated insulin resistance and ovulatory dysfunction. Combined oral contraceptives address hyperandrogenism. GLP-1 RA chronic weight management addresses obesity-related insulin resistance per FDA-approved indications. Endocrinology, OB-GYN, and reproductive endocrinology coordination ensures comprehensive care.
Are these peptides legal in the United States?
Liraglutide is FDA-approved as Saxenda by Novo Nordisk for chronic weight management by prescription. Semaglutide is FDA-approved as Wegovy by Novo Nordisk for chronic weight management by prescription. Tirzepatide is FDA-approved as Zepbound by Eli Lilly for chronic weight management by prescription. Retatrutide is investigational; access is through clinical trial enrollment. Compounded GLP-1 receptor agonists are available through 503A pharmacies during commercial supply shortages but represent non-validated practice. Always work with a licensed prescriber within validated medical framework.
How long does it take to see insulin sensitivity improvements?
Insulin sensitivity improvements develop progressively with weight loss and lifestyle intervention. The Diabetes Prevention Program demonstrated significant T2D progression reduction over 3 years with sustained intervention. GLP-1 RA chronic weight management produces progressive weight reduction over 56 to 72 weeks in Phase 3 trials with corresponding insulin sensitivity benefits. Glycemic measures including HbA1c improve over weeks to months. Sustained intervention is required for sustained benefit. Comprehensive monitoring under specialty guidance ensures appropriate progress assessment.
Should I still prioritize lifestyle if I am taking GLP-1 RA for weight management?
Yes. Lifestyle intervention remains foundational alongside any pharmacotherapy. Mediterranean dietary pattern provides substantial validated cardiometabolic outcomes evidence. Physical activity 150 minutes moderate intensity weekly per ADA improves insulin sensitivity. Adequate sleep supports metabolic regulation. Stress management addresses cortisol effects. The DPP framework demonstrated 58 percent T2D reduction through lifestyle intervention. GLP-1 RA chronic weight management complements but does not replace lifestyle foundations.
What about MASLD and insulin resistance?
Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) is closely associated with insulin resistance. Approximately 25 percent of US adults have MASLD. Comprehensive evaluation includes liver function tests (ALT, AST), liver imaging, and FibroScan or liver biopsy when appropriate. Resmetirom (Rezdiffra) was FDA-approved in 2024 for MASH with moderate to advanced fibrosis. Lifestyle intervention and weight management form the foundation. Semaglutide ESSENCE Phase 3 trial program studies MASLD applications. Hepatology coordination ensures appropriate evaluation and management.
What questions should I ask my doctor about peptides for insulin resistance?
Ask: (1) What is my comprehensive evaluation including HbA1c, fasting glucose, OGTT, lipid panel, BMI, and cardiovascular risk? (2) Is lifestyle intervention through DPP-derived framework appropriate as first-line? (3) Do I have specific indications for metformin per ADA Standards of Care? (4) For my situation, do FDA-approved chronic weight management options apply (Saxenda, Wegovy, Zepbound)? (5) How do contraindications apply (medullary thyroid carcinoma history, pancreatitis history, pregnancy planning)? (6) What is my realistic timeline and monitoring plan?
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.